2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Devices, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Computer Vision, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Systems-Based Hematology, Value, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Embryo/Fetus, Pediatric, Pregnant, Young Adult
PAPER

1180 Preliminary results from DISC-3405-102: A phase 1b study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with sickle cell disease

Susanna Curtis, MD, PhD, Laura M. DeCastro, MD2, Amro Elshoury, MD3, Robert Ward Hagar, MD4, Abdullah Kutlar, MD5, Darla Liles, MD6, Charles T Quinn, MD, MS7, Santosh L Saraf, MD8, John Joseph Strouse, MD, PhD9, Shuai Chen, PhD, MS10, Daphne Yang11, Marcus Carden, MD, MSc12, Will Savage, MD, PhD13, Fuad El Rassi, MD14, Julie Kanter, MD15
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 University of Pittsburgh Medical Center, Pittsburgh, United States
3 Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
4 University of California San Francisco Benioff Children’s Hospitals, Oakland, California, United States
5 Augusta University Medical College of Georgia, Augusta, Georgia, United States
6 Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States
7 Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States
8 University of Illinois Medical Center, Chicago, Illinois, United States
9 Duke University School of Medicine, Durham, North Carolina, United States
10 Disc Medicine, Watertown, Massachusetts, United States
11 Disc Medicine, Watertown, Massachusetts, United States
12 Disc Medicine, Watertown, Massachusetts, United States
13 Disc Medicine, Watertown, Massachusetts, United States
14 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
15 he University of Alabama at Birmingham, School of Medicine, Birmingham, Alabama, United States

Background: There remains an unmet need for novel therapies to address pain and other morbidities in sickle cell disease (SCD). Preclinical and clinical evidence suggest that reducing iron availability may be a potential therapeutic strategy to reduce hemoglobin S (HbS) concentration (ie, mean corpuscular hemoglobin concentration [MCHC]) in red blood cells (RBCs) and, consequently, the concentration-dependent HbS polymerization that drives pathophysiology. Patients with SCD without iron overload also often have lower levels of hepcidin, the key regulator of iron homeostasis (Manganokar et al, Br J Haematol 2020). Thus, hepcidin induction with resultant iron restriction may reduce hemolytic and vaso-occlusive complications and their downstream sequelae in SCD. 

DISC-3405 is an investigational, novel, humanized (Ig) G1 monoclonal antibody (mAb) that targets transmembrane serine protease 6 (TMPRSS6, also known as matriptase 2) to stimulate endogenous hepcidin production. In an SCD mouse model, treatment with r4K12B (a DISC-3405 mouse analog) resulted in iron-restricted erythropoiesis and a significant decrease in hemolysis and inflammation markers (Giannini et al, Blood 2024). In a randomized, placebo-controlled Phase 1 study in healthy volunteers (DISC-3405-101; NCT06050915), DISC-3405 at doses between 37.5-300 mg was well-tolerated, resulted in dose-dependent pharmacokinetic (PK) changes, significantly increased hepcidin production with corresponding reductions in serum iron levels, and reduced MCHC (Liu et al, Blood 2024; Liu et al, HemaSphere 2025). 

DISC-3405-102 (NCT07187973) is an open-label, multicenter, within-participant dose-escalation Phase 1b study enrolling up to 24 patients in the US that will assess safety, tolerability, PK, pharmacodynamics (PD), and therapeutic effect of hepcidin induction and iron restriction in participants with SCD. 

Methods: Eligible participants are treated and followed for 20 weeks and given up to 3 escalating doses (75, 150, 300 mg) spaced 4-8 weeks apart. Participants may continue in an optional 12-week maintenance period where additional safety and efficacy will be assessed. 

The primary endpoint is to determine the safety and tolerability profile of DISC-3405 in the population. Secondary endpoints include changes in hemolysis markers and PK. Exploratory endpoints include patient-reported outcome measures, changes and incidence of clinical measures of SCD (eg, vaso-occlusive events, transfusions, hospitalizations), changes in markers of iron homeostasis, and measures of RBC deformability and whole-blood viscosity. A safety review committee aids in the monitoring of emerging study data to ensure ongoing participant safety. 

Eligible participants include adults aged ≥18 years with hemoglobin SS (HbSS; sickle cell anemia) or hemoglobin SC (HbSC; hemoglobin SC disease) and normal alpha globin gene screen, hemoglobin levels ≥7 g/dL (the first 2 participants must have hemoglobin ≥9), reticulocyte counts >1.5 x upper limit of normal, transferrin saturation (TSAT) ≥15%, and ferritin 50-1000 ng/mL. Participants should have evidence of SCD-related complications, including 1-10 vaso-occlusive pain episodes in the past 12 months or a history of other forms of end organ damage. Stable doses for at least 2 months prior to screening of hydroxyurea, L-glutamine, or crizanlizumab are allowed. Key exclusion criteria include participants who require regular transfusions, hospitalization within 14 days of screening, hepatic dysfunction, and estimated glomerular filtration rate of <60 mL/min/1.73 m2. 

Results: Four adults (3 male; age range 31-44 years) have been enrolled as of July 13, 2026: 3 participants with HbSS and 1 participant with HbSC. Three participants are on hydroxyurea. At baseline, mean (range) hemoglobin was 10.5 g/dL (8.2-12.2), and TSAT, ferritin, and erythropoietin were 44.3% (25-87%), 304.3 ng/mL (79-795), and 224.8 mU/mL (37-555), respectively. Mean (range) number of vaso-occlusive events in the 12 months prior to screening was 1 (0-2). Other medical history complications included retinopathy, priapism, avascular necrosis, and acute chest syndrome. Updated preliminary safety and efficacy results, reflecting additional participant enrollment and follow-up, will be presented. 

Conclusions: DISC-3405 is an investigational, novel, humanized mAb antibody that stimulates endogenous production of hepcidin and leads to iron restriction, which may have benefit in individuals living with SCD.

Marcus Carden, MD, MSc: Disc Medicine - Stock (publicly traded); Disc Medicine - Current Employment